Sichuan Baili Pharmaceutical Co., Ltd.

This early-phase study tests a new drug called BL-M02D1 in about 82 people with advanced triple negative breast cancer or other solid tumors that have spread and are not curable with current treatments. The main goals are to check the drug's safety, find the best dose, and see if…

This early-phase study tests a new drug called GNC-035 in people whose chronic lymphocytic leukemia (CLL) has come back or stopped responding to treatment. The drug is a tetra-specific antibody designed to attack cancer cells in multiple ways. The main goals are to check the drug…

This study tests a new drug combination (SI-B001 plus osimertinib) in people with advanced non-small cell lung cancer that has stopped responding to standard treatments. About 14 adults with specific genetic mutations will receive the combo to see if it shrinks tumors and how saf…

This early-stage study tests a new drug called SI-B001 in about 60 people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to target two cancer-related proteins, EGFR and HER3. The main goals are to check safety…

This study tests a new drug called SI-B001 combined with paclitaxel in 42 adults with head and neck cancer that has returned or spread. Participants had already tried standard treatments. The goal is to see if the combination shrinks tumors and is safe. This is an early-phase tri…

This study tests a new drug called BL-B01D1 against standard chemotherapy in people with advanced nasopharyngeal cancer that has not responded to at least two prior treatments. About 386 adults will be randomly assigned to receive either the new drug or a doctor-chosen chemothera…

This study tests a new drug called BL-B01D1 in 27 people with advanced chordoma, a rare bone cancer that has spread or cannot be removed by surgery. The main goal is to see if the drug can shrink tumors. Participants receive the drug and are monitored for safety and how long the …

This early-phase study tests a new drug called BL-M02D1 in 22 adults with advanced digestive tract or other solid tumors that cannot be cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants…

This phase 3 study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has returned or spread. It is for patients whose cancer did not respond to or stopped responding to initial treatment with immunotherapy and platinum-…

This early-phase study tests a new drug called BL-B01D1 in people with advanced urinary or other solid tumors that cannot be cured or have no standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Only 4 particip…

This study tests a new drug called GNC-038 in people with central nervous system lymphoma that has come back or not responded to treatment. The drug is a special antibody designed to attack cancer cells in the brain and spinal cord. The main goals are to find a safe dose and see …

This study tests an experimental drug called SI-B001 in 11 adults with advanced head and neck cancer that has spread or returned after standard treatments like chemotherapy and immunotherapy. The goal is to see if the drug can shrink tumors and how safe it is. Participants receiv…

This study compares a new drug, BL-B01D1, with the standard chemo docetaxel in people with advanced non-small cell lung cancer that has not responded to prior treatments. About 698 participants will be randomly assigned to receive either BL-B01D1 or docetaxel. The main goal is to…

This study tests a new drug called SI-B001 combined with chemotherapy in 69 adults with advanced non-small cell lung cancer that no longer responds to standard treatments. The goal is to see if the combination can shrink tumors or slow the disease. Participants must have a specif…

This study tests a new drug called BL-M07D1, alone or with other medications, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if the drug shrinks tumors and how safe it is. About 83 adults aged 18 to …

This study tests a combination of two drugs, SI-B001 and irinotecan, in people with advanced esophageal cancer that has come back or spread and no longer responds to standard treatments. The goal is to see if the combo can shrink tumors and how safe it is. About 22 adults aged 18…

This phase 3 study tests whether the experimental drug BL-B01D1 works better than standard chemotherapy for people with advanced HR+HER2- breast cancer that has not responded to at least one prior chemo. About 383 participants will receive either BL-B01D1 or a doctor-chosen chemo…

This early-stage study tests a new drug called GNC-035 in people with advanced breast cancer that has spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 36 adults will take part.

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have not responded to standard treatments. The drug is a bispecific antibody designed to target two immune checkpoints (PD-1 and CTLA-4) to help the immune system fight cancer. The…

This early-phase study tests a new drug called GNC-035 in 33 adults with blood cancers that have come back or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The drug is a special antibody d…

This phase 3 study compares a new drug, BL-B01D1, to standard chemotherapy in 418 people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth and extend survival. Participants receive…

This phase 3 study compares a new drug, BL-B01D1, with standard chemotherapy in 432 adults with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to EGFR-targeted pills. The main goal is to see if BL-B01D1 can delay cancer growth or …

This early-phase study tests an experimental drug called GNC-038 in people with certain lymphomas (NK/T-cell lymphoma, AITL, and other non-Hodgkin lymphomas) that have returned or not responded to standard therapy. The main goals are to check the drug's safety, find the best dose…

This study compares a new drug, BL-B01D1, to the standard drug topotecan in 722 adults with small cell lung cancer that came back after prior treatments. The goal is to see if BL-B01D1 helps people live longer. Participants must have already tried immunotherapy and chemotherapy w…

This early-stage trial tests a new drug called GNC-038, a quad-specific antibody designed to attack cancer cells in people with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia. The main goals are to check the drug's safety, find the right dose, and see…

This study tests a new drug called BL-B01D1, given alone or with another drug (osimertinib), in people with advanced non-small cell lung cancer that has spread. The goal is to see if the treatment shrinks tumors and is safe. About 198 adults with this type of lung cancer will tak…

This study tests a new drug called GNC-038 in 12 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. It is an early-phase trial to gather …

This study tests a new drug called BL-M02D1 in people with advanced solid tumors, including non-small cell lung cancer that has not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 14 adults will take part in this ea…